Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPY1R-targeting peptide-drug conjugate
- Development stage
- Preclinical
- Lead developer
- MolGenie
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Oral, Intraperitoneal
01
Overview
This NPY1R-targeting peptide-drug conjugate is an experimental therapeutic candidate being developed by MolGenie and Valdospan for the treatment of various solid tumors, including breast cancer, Ewing sarcoma, melanoma, pancreatic cancer, and prostate cancer. The conjugate consists of a peptide ligand derived from or analogous to Neuropeptide Y (NPY) that specifically binds to the Neuropeptide Y receptor type 1 (NPY1R). NPY1R is frequently overexpressed in several human cancers while having limited expression in healthy tissues, providing a basis for targeted delivery. Upon binding to the receptor, the PDC is internalized through receptor-mediated endocytosis, allowing for the intracellular release of a cytotoxic payload to induce cell death. The program is currently in the preclinical stage of development.
- Other names
- NPY1R-targeting PDCNPY-1R-targeting PDCNPY 1R-targeting PDCNPY1R-targeting peptide-drug conjugate (MolGenie/Valdospan)
02
Targets
NPY1R (Neuropeptide Y receptor Y1)
Beyond the preview
Go deeper on NPY1R-targeting peptide-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NPY1R-targeting peptide-drug conjugate.